大摩:下半年盈利仍受壓,予信義光能(0968.HK)“增持”評級,目標價17港元
摩根士丹利發表研究報吿表示,信義光能近日發盈喜指今年上半年純利按年升100%-120%至28億-31億元人民幣,但今年下半年太陽能玻璃業務受壓,隨着多晶硅價格上漲,對太陽能產能的需求減少,而太陽能玻璃價格亦受壓,預期相關業務的銷售量增加能部分抵銷價格下降的影響,但今年下半年整體盈利仍然受壓。大摩仍予公司“增持”評級,目標價17港元。
大摩表示,公司面對的上行風險為產能擴展計劃較早完成,及與信義玻璃產生協同效應能減少更多成本。信義光能(0968.HK)現報13.72港元,市值1209億港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.